3F0 Stock Chart & Stats
€0.08
--
Market closed
€0.08
--
Day’s Range― - ―
52-Week Range€0.04 - €0.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€1.95M
Enterprise Value€2.98M
Total Cash (Recent Filing)€2.64M
Total Debt (Recent Filing)€2.33M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding31,261,782
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.30
Price to Sales (P/S)0.41
P/FCF Ratio-7.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.33Price Target Upside312.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€8.70M
Bulls Say, Bears Say
Bulls Say
High Gross MarginA ~45.5% trailing gross margin indicates durable product-level profitability and pricing power in OTC wellness. That margin can absorb distribution and marketing spend as revenue scales, improving odds of moving to sustainable operating profitability if top-line stabilizes.
Positive Equity CushionA positive equity base of roughly $2.9M provides a measurable balance-sheet cushion vs. insolvency and supports short-term operations. This retained capital and positive book value give management flexibility to fund strategic investments or weather continued losses without immediate distress.
Improving Cash-burn TrendCash burn has materially improved from the extreme levels in 2021–2022, signaling operational progress and tighter cost control. A sustained improvement trend reduces refinancing risk and increases the chance cash generation will turn positive over the medium term if revenue stabilizes.
Bears Say
Declining Revenue TrendA 14.1% TTM revenue decline reverses prior growth and signals weakening demand or distribution execution. Persistent top-line contraction undermines operating leverage, makes fixed-cost absorption harder, and prolongs the path to profitability absent a credible revenue-recovery plan.
Ongoing UnprofitabilitySustained negative operating and net margins (~-9%) mean the core business is not generating earnings to fund reinvestment. Continued losses erode equity over time, limit ability to self-fund growth initiatives, and increase dependence on external financing to execute strategy.
Negative Operating Cash Flow And Rising LeverageNegative operating and free cash flow (~-$0.3M) combined with rising leverage (debt-to-equity ~0.79) reduce financial flexibility. This dynamic increases refinancing risk and constrains investments, raising execution risk if revenue and margins do not improve to restore self-funding capacity.
Delivra Health Brands News
3F0 FAQ
What was Delivra Health Brands’s price range in the past 12 months?
Delivra Health Brands lowest stock price was €0.04 and its highest was €0.20 in the past 12 months.
What is Delivra Health Brands’s market cap?
Delivra Health Brands’s market cap is €1.95M.
When is Delivra Health Brands’s upcoming earnings report date?
Delivra Health Brands’s upcoming earnings report date is Oct 23, 2026 which is in 92 days.
How were Delivra Health Brands’s earnings last quarter?
Delivra Health Brands released its earnings results on May 29, 2026. The company reported -€0.019 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.019.
Is Delivra Health Brands overvalued?
According to Wall Street analysts Delivra Health Brands’s price is currently Undervalued.
Does Delivra Health Brands pay dividends?
Delivra Health Brands does not currently pay dividends.
What is Delivra Health Brands’s EPS estimate?
Delivra Health Brands’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Delivra Health Brands have?
Delivra Health Brands has 31,261,782 shares outstanding.
What happened to Delivra Health Brands’s price movement after its last earnings report?
Delivra Health Brands reported an EPS of -€0.019 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.947%.
Which hedge fund is a major shareholder of Delivra Health Brands?
Currently, no hedge funds are holding shares in DE:3F0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Delivra Health Brands
Based in Vancouver, Canada, Delivra Health Brands Inc., through its various subsidiaries, distributes an assortment of lifestyle and wellness goods to a global clientele of consumers and medical patients within regulated jurisdictions. The firm's product line includes cannabis, liquid sleep supplements, powdered sleep aids, edible gummies, and topical pain relief solutions. These items are available under well-known brand labels like LivRelief, Dream Water, and LivRelief Infused. The company was formerly recognized as Harvest One Cannabis Inc.
3F0 Stock 12 Month Forecast
Average Price Target
€0.33
▲(312.89% Upside)